Biomimetic hydroxyapatite-chitosan nanoparticles deliver the erythromycin for improved antibacterial activity

Antibiotics administration to treat bacterial infections causing systemic toxicity due to the inapropriate usage. Therefore, a method for treating bacterial infections that can maintain the concentration of antibiotics for a long period of release without exceeding systemic toxicity. In this study, we developed a composite composed of chitosan (CS) and natural hydroxyapatite (HAP) extracted from chicken bone to deliver the Erythromycin (Ery) for enhanced treatment of bacterial infections. The results showed that CS-HAP-Ery NPs have an average particle size of 100–200 nm with a positive zeta potential of 18.4 mV. The optimum Ery encapsulation and loading efficiency was found at 69.28 ± 0.77% and 16.07 ± 0.10% respectively. Further, the CS-HAP-Ery NPs considerably inhibited the growth and biofilm formation of B. cereusand S. entrica. Moreover, CS-HAP-Ery NPs did not show toxicity in hemolytic and CAM assays.